4 active not recruiting, 4 recruiting, 2 completed. 10 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Active not recruiting 4, Recruiting 4, Completed 2 |
| Phase 2 | 5 | Active not recruiting 3, Recruiting 2 |
Follow AZD5305: new trials by email Literature Review of AZD5305 trials Research Report on AZD5305
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs AZD9750, AZD5305 - Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 6 | 2026-01-27 | 2026-10-02 |
| AZD5305 hADME in Patients With Advanced Solid Malignancies Saruparib (AZD5305), [14C]-AZD5305 microtracer, [14C]-AZD5305 (therapeutic dose) - Locally Advanced or Metastatic Solid Tumor | Phase 1 | Recruiting | AstraZeneca | 8 | 2025-04-02 | 2026-11-12 |
| A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer. Saruparib (AZD5305), Darolutamide, No Treatment - Prostate Cancer | Phase 1 | Completed | AstraZeneca | 113 | 2023-09-21 | 2026-06-30 |
| Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors Torvutatug samrotecan, Saruparib, Bevacizumab - Ovarian Cancer, Lung Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 622 | 2023-06-05 | 2026-10-05 |
| Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies AZD5305, Itraconazole - Advanced Solid Malignancies | Phase 1 | Completed | AstraZeneca | 16 | 2022-11-07 | 2024-06-18 |
| Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer AZD5305, Enzalutamide, Abiraterone Acetate - Metastatic Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 174 | 2022-06-02 | 2026-08-26 |
| A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib) - Breast Cancer, Biliary Tract Carcinoma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 460 | 2021-10-18 | 2026-10-13 |
| A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC Radiotherapy, Olaparib Oral Tablet [Lynparza], AZD1390 - Non Small Cell Lung Cancer | Phase 1 | Recruiting | University of Leeds | 200 | 2021-03-17 | 2025-12-19 |
| Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies AZD5305, Paclitaxel, Carboplatin - Ovarian Cancer, Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 702 | 2020-11-12 | 2026-09-21 |
| Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents Administration of ceralasertib, Administration of ceralasertib in combination with olaparib, Administation of ceralasertib in combination with durvalumab - Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer | Phase 1 | Active not recruiting | AstraZeneca | 358 | 2014-10-31 | 2026-07-24 |
Ovarian Neoplasms (4) · Prostatic Neoplasms (4) · Endometrial Neoplasms (3) · Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Adenocarcinoma of Lung (1) · Biliary Tract Neoplasms (1) · Bulbo-Spinal Atrophy, X-Linked (1) · Colorectal Neoplasms (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Stomach Neoplasms (1) · Urinary Bladder Neoplasms (1) · Uterine Cervical Neoplasms (1)
AstraZeneca (9) · University of Leeds (1)
United Kingdom (9) · United States (7) · Australia (6) · Canada (4) · Japan (4) · South Korea (4) · Spain (4) · China (3) · Italy (3) · Hungary (2) · Netherlands (2) · Poland (2) · Taiwan (2) · Belgium (1) · Czechia (1)
Alastair Greystoke, MB ChB, MSc, PhD (1) · Corinne Faivre-Finn, MD, PhD (1) · Funda Meric-Bernstam, MD (1) · Timothy Yap (1)
PMID 34904813, PMID 35929986, PMID 36446040, PMID 39392424, PMID 41917211, PMID 42816529
2023 (3), 2014 (1)